Targeting TGF-beta Superfamily Biology
Best-In-Class Ligand Traps for Diseases of High Unmet Medical Need
Connecting science and passion to deliver
35Pharma is a biopharmaceutical company that designs and develops
innovative biologics for diseases of high unmet medical need.
We believe in connecting rigorous science with our innate sense of urgency to
rapidly generate breakthrough therapies for patients in need of a better quality of life.
Our highly qualified team of drug developers and company builders has a
track record of advancing complex biologics from discovery through clinical trials.
Rational design fueled by
years of experience
Our strength is combining superior protein engineering
expertise with a deep understanding of TGF-beta structure-function
relationships to rationally design highly potent ligand traps.
Our in-house team of experienced manufacturing scientists
rigorously evaluates all drug candidates to ensure excellent
manufacturability as part of candidate selection.
Our Leadership Team and Board of Directors combine years of experience in developing complex biologics with a successful track record in company creation, private and public financings, as well as Pharma partnerships.
Learn more below!
A mission to radically transform
We believe in building effective teams that value taking action on the best ideas
to develop new breakthrough therapies at industry leading pace. Our beautiful
20,000 square feet R&D facilities are located in the heart of Montreal, Canada,
and comprise laboratory space for pre-clinical research as well as process
development that bolster our mission to serve patients in need.
Read Our Latest News
35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced that it has been selected for an oral presentation at the 2024 American Thoracic Society (ATS) International Conference in San Diego, CA, USA (May 17 – 22, 2024). The presentation will feature data on HS135, the Company’s Phase 1 novel Activin […]
Montréal, QC, Canada (Jan 31, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced it will be participating at the following investor conferences: Evercore ISI’s 2024 Emerging Private Biotech Conference Leerink Partners Global Biopharma Conference 2024 About 35Pharma 35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the treatment […]
Montréal, QC, Canada (Jan 25, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced the appointment of seasoned drug development executive Guy Braunstein, MD, PhD, to its Board of Directors. Graham Walmsley, MD, PhD, also joined the board as an observer. “Guy’s successful track record in rapidly progressing numerous agents from early […]